Stockreport

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024NK-Cell engager SAR443579/IPH61011 first-in-human study advanced t [Read more]